Cargando…

2449. Validation of In Vitro Activity of Aminoglycosides Against Recently Isolated Helicobacter pylori for Commercialization of Gentamicin-Intercalated Smectite Hybrid as a New Therapeutic Agent

BACKGROUND: The eradication rate of Helicobacter pylori as a standard therapy based on amoxicillin and clarithromycin, exhibits a decreasing trend. Alternative approaches have been explored, but there is still controversy in the regimen change and these do not provide a satisfactory substitute to th...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Kyoung Hwa, Park, Soon Young, Yoo, Seul Gi, Kwon, Da Eun, Jeong, Su Jin, Jung, Da Hyun, Kim, Jie-Hyun, Jeong, Seok Hoon, Kang, Il-Mo, Song, Young Goo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254595/
http://dx.doi.org/10.1093/ofid/ofy210.2102
_version_ 1783373752041472000
author Lee, Kyoung Hwa
Park, Soon Young
Yoo, Seul Gi
Kwon, Da Eun
Jeong, Su Jin
Jung, Da Hyun
Kim, Jie-Hyun
Jeong, Seok Hoon
Kang, Il-Mo
Song, Young Goo
author_facet Lee, Kyoung Hwa
Park, Soon Young
Yoo, Seul Gi
Kwon, Da Eun
Jeong, Su Jin
Jung, Da Hyun
Kim, Jie-Hyun
Jeong, Seok Hoon
Kang, Il-Mo
Song, Young Goo
author_sort Lee, Kyoung Hwa
collection PubMed
description BACKGROUND: The eradication rate of Helicobacter pylori as a standard therapy based on amoxicillin and clarithromycin, exhibits a decreasing trend. Alternative approaches have been explored, but there is still controversy in the regimen change and these do not provide a satisfactory substitute to the existing standard therapy. Thus, a novel and efficient H. pylori eradication regimen should be developed. Smectite can serve as a drug delivery system and gentamicin-intercalated smectite hybrids (S-GEN) are expected to supersede the standard therapy for H. pylori eradication. In the previous study, we synthesized S-GEN complexes as a novel therapeutic agent. In a murine model, S-GEN released gentamicin to the gastric wall stably and the therapeutic effect was not inferior to the conventional standard therapy. The aim of this study was to confirm whether the minimum inhibitory concentration (MIC) of aminoglycosides applied as smectite hybrids remained low against recently isolated H. pylori strains. METHODS: The H. pylori strains were collected via endoscopic biopsy from 1,422 patients at Gangnam Severance Hospital in Seoul, Korea, between March 2015 and February 2018. Antimicrobial susceptibility tests were performed, and the MICs of eight antibiotics (amoxicillin, clarithromycin, metronidazole, tetracycline, levofloxacin, gentamicin, netilmicin, and tobramycin) were determined by using the Epsilometer test and following the European Committee on Antimicrobial Susceptibility Testing recommendations. RESULTS: Finally, 140 H. pylori strains were analyzed in this study. The resistance rate to clarithromycin was 30.7%, although it is a major antimicrobial agent used in standard therapy. The MIC(50) and MIC(90) of gentamicin (MIC(50) 0.25 mg/L, MIC(90) 0.75 mg/L) and netilmicin (MIC(50) 0.19 mg/L, MIC(90) 0.75 mg/L) were lower than that of metronidazole, tetracycline and levofloxacin, which are alternative therapies for H. pylori eradication. In clarithromycin-resistant strains, the MIC(50) was 0.25 mg/L and the MIC(90) was 1 mg/L for gentamicin; for netilmicin, the values were 0.25 mg/L and 0.75 mg/L, respectively. CONCLUSION: Through the use of gentamicin and netilmicin, which have low MICs for H. pylori, aminoglycoside-intercalated smectite hybrids are expected to emerge as a new standard therapy for H. pylori eradication. DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6254595
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-62545952018-11-28 2449. Validation of In Vitro Activity of Aminoglycosides Against Recently Isolated Helicobacter pylori for Commercialization of Gentamicin-Intercalated Smectite Hybrid as a New Therapeutic Agent Lee, Kyoung Hwa Park, Soon Young Yoo, Seul Gi Kwon, Da Eun Jeong, Su Jin Jung, Da Hyun Kim, Jie-Hyun Jeong, Seok Hoon Kang, Il-Mo Song, Young Goo Open Forum Infect Dis Abstracts BACKGROUND: The eradication rate of Helicobacter pylori as a standard therapy based on amoxicillin and clarithromycin, exhibits a decreasing trend. Alternative approaches have been explored, but there is still controversy in the regimen change and these do not provide a satisfactory substitute to the existing standard therapy. Thus, a novel and efficient H. pylori eradication regimen should be developed. Smectite can serve as a drug delivery system and gentamicin-intercalated smectite hybrids (S-GEN) are expected to supersede the standard therapy for H. pylori eradication. In the previous study, we synthesized S-GEN complexes as a novel therapeutic agent. In a murine model, S-GEN released gentamicin to the gastric wall stably and the therapeutic effect was not inferior to the conventional standard therapy. The aim of this study was to confirm whether the minimum inhibitory concentration (MIC) of aminoglycosides applied as smectite hybrids remained low against recently isolated H. pylori strains. METHODS: The H. pylori strains were collected via endoscopic biopsy from 1,422 patients at Gangnam Severance Hospital in Seoul, Korea, between March 2015 and February 2018. Antimicrobial susceptibility tests were performed, and the MICs of eight antibiotics (amoxicillin, clarithromycin, metronidazole, tetracycline, levofloxacin, gentamicin, netilmicin, and tobramycin) were determined by using the Epsilometer test and following the European Committee on Antimicrobial Susceptibility Testing recommendations. RESULTS: Finally, 140 H. pylori strains were analyzed in this study. The resistance rate to clarithromycin was 30.7%, although it is a major antimicrobial agent used in standard therapy. The MIC(50) and MIC(90) of gentamicin (MIC(50) 0.25 mg/L, MIC(90) 0.75 mg/L) and netilmicin (MIC(50) 0.19 mg/L, MIC(90) 0.75 mg/L) were lower than that of metronidazole, tetracycline and levofloxacin, which are alternative therapies for H. pylori eradication. In clarithromycin-resistant strains, the MIC(50) was 0.25 mg/L and the MIC(90) was 1 mg/L for gentamicin; for netilmicin, the values were 0.25 mg/L and 0.75 mg/L, respectively. CONCLUSION: Through the use of gentamicin and netilmicin, which have low MICs for H. pylori, aminoglycoside-intercalated smectite hybrids are expected to emerge as a new standard therapy for H. pylori eradication. DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2018-11-26 /pmc/articles/PMC6254595/ http://dx.doi.org/10.1093/ofid/ofy210.2102 Text en © The Author(s) 2018. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Lee, Kyoung Hwa
Park, Soon Young
Yoo, Seul Gi
Kwon, Da Eun
Jeong, Su Jin
Jung, Da Hyun
Kim, Jie-Hyun
Jeong, Seok Hoon
Kang, Il-Mo
Song, Young Goo
2449. Validation of In Vitro Activity of Aminoglycosides Against Recently Isolated Helicobacter pylori for Commercialization of Gentamicin-Intercalated Smectite Hybrid as a New Therapeutic Agent
title 2449. Validation of In Vitro Activity of Aminoglycosides Against Recently Isolated Helicobacter pylori for Commercialization of Gentamicin-Intercalated Smectite Hybrid as a New Therapeutic Agent
title_full 2449. Validation of In Vitro Activity of Aminoglycosides Against Recently Isolated Helicobacter pylori for Commercialization of Gentamicin-Intercalated Smectite Hybrid as a New Therapeutic Agent
title_fullStr 2449. Validation of In Vitro Activity of Aminoglycosides Against Recently Isolated Helicobacter pylori for Commercialization of Gentamicin-Intercalated Smectite Hybrid as a New Therapeutic Agent
title_full_unstemmed 2449. Validation of In Vitro Activity of Aminoglycosides Against Recently Isolated Helicobacter pylori for Commercialization of Gentamicin-Intercalated Smectite Hybrid as a New Therapeutic Agent
title_short 2449. Validation of In Vitro Activity of Aminoglycosides Against Recently Isolated Helicobacter pylori for Commercialization of Gentamicin-Intercalated Smectite Hybrid as a New Therapeutic Agent
title_sort 2449. validation of in vitro activity of aminoglycosides against recently isolated helicobacter pylori for commercialization of gentamicin-intercalated smectite hybrid as a new therapeutic agent
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6254595/
http://dx.doi.org/10.1093/ofid/ofy210.2102
work_keys_str_mv AT leekyounghwa 2449validationofinvitroactivityofaminoglycosidesagainstrecentlyisolatedhelicobacterpyloriforcommercializationofgentamicinintercalatedsmectitehybridasanewtherapeuticagent
AT parksoonyoung 2449validationofinvitroactivityofaminoglycosidesagainstrecentlyisolatedhelicobacterpyloriforcommercializationofgentamicinintercalatedsmectitehybridasanewtherapeuticagent
AT yooseulgi 2449validationofinvitroactivityofaminoglycosidesagainstrecentlyisolatedhelicobacterpyloriforcommercializationofgentamicinintercalatedsmectitehybridasanewtherapeuticagent
AT kwondaeun 2449validationofinvitroactivityofaminoglycosidesagainstrecentlyisolatedhelicobacterpyloriforcommercializationofgentamicinintercalatedsmectitehybridasanewtherapeuticagent
AT jeongsujin 2449validationofinvitroactivityofaminoglycosidesagainstrecentlyisolatedhelicobacterpyloriforcommercializationofgentamicinintercalatedsmectitehybridasanewtherapeuticagent
AT jungdahyun 2449validationofinvitroactivityofaminoglycosidesagainstrecentlyisolatedhelicobacterpyloriforcommercializationofgentamicinintercalatedsmectitehybridasanewtherapeuticagent
AT kimjiehyun 2449validationofinvitroactivityofaminoglycosidesagainstrecentlyisolatedhelicobacterpyloriforcommercializationofgentamicinintercalatedsmectitehybridasanewtherapeuticagent
AT jeongseokhoon 2449validationofinvitroactivityofaminoglycosidesagainstrecentlyisolatedhelicobacterpyloriforcommercializationofgentamicinintercalatedsmectitehybridasanewtherapeuticagent
AT kangilmo 2449validationofinvitroactivityofaminoglycosidesagainstrecentlyisolatedhelicobacterpyloriforcommercializationofgentamicinintercalatedsmectitehybridasanewtherapeuticagent
AT songyounggoo 2449validationofinvitroactivityofaminoglycosidesagainstrecentlyisolatedhelicobacterpyloriforcommercializationofgentamicinintercalatedsmectitehybridasanewtherapeuticagent